We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


CEVEC and Catalent Pharma Solutions Offer Joint Cell Line Development Service

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "CEVEC and Catalent Pharma Solutions Offer Joint Cell Line Development Service"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

CEVEC Pharmaceuticals, and Catalent Pharma Solutions, have announced a joint commercial cell line development service for pharma and biotech customers worldwide.

The offering combines the benefits of CEVEC’s human cell line, CAP-Technology, with Catalent’s unique GPEx® (Gene Product Expression) Technology to generate high expressing stable human cell lines in a much shorter timeframe than traditional methods.

“We are very pleased to be working with Catalent and their truly unique technology to generate stable lines“ said Dr. Rainer Lichtenberger, CEO of CEVEC.

“Several months of testing convincingly showed combining CAP cells and GPEx technology is a very powerful approach. We achieved yields exceeding 3 g/L for a very complex protein produced in our human production cell lines in a very short time frame” added Wolfgang Kintzel, Managing Director and CCO of CEVEC.

Kintzel continued, “The combined offering is a very compelling value proposition for clients looking to outsource cell line development and potential downstream cGMP upscaling while looking for the highest quality using a human cell line.”

“Catalent has been collaborating with customers and suppliers to accelerate biologics development for more than ten years. This exciting collaboration with CEVEC will offer biotech companies developing recombinant proteins and antibodies the advantage of two technologies in one system, enabling them to get a clone candidate in less than 5 months and significantly reducing their time to clinic” stated Scott Houlton, President, Development & Clinical Services.

Houlton continued, “The GPEx technology has been used to express more than 380 different molecules and our integrated development and manufacturing services allow us to take our customers through their clinical trials in the fastest, most cost effective manner.”